<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790775</url>
  </required_header>
  <id_info>
    <org_study_id>94312</org_study_id>
    <nct_id>NCT02790775</nct_id>
  </id_info>
  <brief_title>Pain and Visual Outcome in Intravitreal Bevacizumab Injection</brief_title>
  <acronym>pain &amp; visual</acronym>
  <official_title>Evaluation of the Pain and Visual Outcome Associated With Location of Intravitreal Bevacizumab Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this double blind clinical trial, 1000 patients suffering from diabetic macular edema,
      age-related macular degeneration, neovascularization due to proliferative diabetic
      retinopathy and cystoid macular edema secondary to retinal vascular occlusions are included.
      Those with the history of Ocular pain prior to the procedure, any contraindication for
      Intravitreal Bevacizumab Injection (IVI), history of any kind of anterior segment conditions
      that could affect pain sensation, history of using systemic analgesic or sedative
      medications, history of previous eye surgery other than for cataract, glaucoma, uveitis and
      bullous keratopathy and poor cooperation in using the visual analogue scale (VAS) are
      excluded from the study. Before starting the treatment all patients undergo complete
      ophthalmic exam , best-corrected visual acuity (BCVA) checking and macular thickness
      measurements using optical coherence tomography (OCT). Patients are randomly assigned to each
      group .Each participant receive one injection in one eye in this study. Pain is measured by
      subjective grading on a Visual Analog Scale (VAS) immediately after IVI. BCVA and OCT would
      be checked again at month one.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date>August 30, 2016</completion_date>
  <primary_completion_date type="Actual">May 30, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>immediately after Intravitreal Bevacizumab Injection</time_frame>
    <description>Visual Analog Scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity (BCVA)</measure>
    <time_frame>preoperative and 1 month postoperatively.</time_frame>
    <description>using Snellen chart</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1004</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Injection Anti-VEGF in quadrant 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection Anti-VEGF in quadrant 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>InjectionAnti-VEGF in quadrant 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>InjectionAnti-VEGF in quadrant 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF in quadrant 1</intervention_name>
    <arm_group_label>Injection Anti-VEGF in quadrant 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF in quadrant 2</intervention_name>
    <arm_group_label>Injection Anti-VEGF in quadrant 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF in quadrant 3</intervention_name>
    <arm_group_label>InjectionAnti-VEGF in quadrant 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF in quadrant 4</intervention_name>
    <arm_group_label>InjectionAnti-VEGF in quadrant 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetic macular edema, age-related macular degeneration, neovascularization due to
             proliferative diabetic retinopathy and cystoid macular edema secondary to retinal
             vascular occlusions

        Exclusion Criteria:

          -  history of Ocular pain prior to the procedure, any contraindication for Intravitreal
             Bevacizumab Injection (IVI), history of any kind of anterior segment conditions that
             could affect pain sensation, history of using systemic analgesic or sedative
             medications, history of previous eye surgery other than for cataract, glaucoma,
             uveitis and bullous keratopathy and poor cooperation in using the visual analogue
             scale (VAS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Islamic Republic of Iran</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2016</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Ophthalmic Research center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

